Cutaneous Mycobacterium chelonae infection in chronic lymphocytic leukaemia.
Dungarwalla
M
M
The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.
Field-Smith
A
A
Jameson
C
C
Riley
U
U
Chapman
A
A
Bunker
C B
CB
Dearden
C E
CE
Matutes
E
E
D000361:Agammaglobulinemia / Q000150:complications; D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D016867:Immunocompromised Host; D007167:Immunotherapy / Q000009:adverse effects; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000188:drug therapy; D008297:Male; D009165:Mycobacterium Infections, Nontuberculous / Q000150:complications* / Q000175:diagnosis / Q000382:microbiology; D016926:Mycobacterium chelonae / Q000302:isolation & purification*; D009894:Opportunistic Infections / Q000150:complications* / Q000175:diagnosis / Q000382:microbiology; D017192:Skin Diseases, Bacterial / Q000150:complications* / Q000175:diagnosis / Q000382:microbiology; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine